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Abstract
Background: Evidence suggests glucose transporter-1(GLUT1) genetic variation affects diabetic nephropathy and
albuminuria. Our aim was to evaluate associations with albuminuria of six GLUT1 single nucleotide polymorphisms
(SNPs), particularly XbaI and the previously associated Enhancer-2(Enh2) SNP.
Methods: A two-stage case-control study was nested in a prospective cohort study of 2156 African Americans and
8122 European Americans with urinary albumin-to-creatinine ratio(ACR). Cases comprised albuminuria(N = 825; ≥
30 μg/mg) and macroalbuminuria(N = 173; ≥ 300 μg/mg). ACR < 30 μg/mg classified controls(n = 9453). Logistic
regression and odds ratios(OR) assessed associations. The evaluation phase(stage 1, n = 2938) tested associations of
albuminuria(n = 305) with six GLUT1 SNPs: rs841839, rs3768043, rs2297977, Enh2(rs841847) XbaI(rs841853), and
rs841858. Enh2 was examined separately in the replication phase(stage 2, n = 7340) and the total combined
sample (n = 10,278), with all analyses stratified by race and type 2 diabetes.
Results: In European Americans, after adjusting for diabetes and other GLUT1 SNPs in stage 1, Enh2 risk genotype
(TT) was more common in albuminuric cases(OR = 3.37, P = 0.090) whereas XbaI (OR = 0.94, p = 0.931) and
remaining SNPs were not. In stage 1, the Enh2 association with albuminuria was significant among diabetic
European Americans(OR = 2.36, P = 0.025). In African Americans, Enh2 homozygosity was rare(0.3%); XbaI was
common(18.0% AA) and not associated with albuminuria. In stage 2(n = 7,340), Enh2 risk genotype had increased
but non-significant OR among diabetic European Americans(OR = 1.66, P = 0.192) and not non-diabetics(OR = 0.99,
p = 0.953), not replicating stage 1. Combining stages 1 and 2, Enh2 was associated with albuminuria(OR 2.14 [1.20-
3.80], P = 0.009) and macroalbuminuria(OR 2.69, [1.02-7.09], P = 0.045) in diabetic European Americans. The Enh2
association with macroalbuminuria among non-diabetic European Americans with fasting insulin(OR = 1.84, P =
0.210) was stronger at the highest insulin quartile(OR = 4.08, P = 0.040).
Conclusions: As demonstrated with type 1 diabetic nephropathy, the GLUT1 Enh2 risk genotype, instead of XbaI,
may be associated with type 2 diabetic albuminuria among European Americans, though an association is not
conclusive. The association among diabetic European Americans found in stage 1 was not replicated in stage 2;
however, this risk association was evident after combining all diabetic European Americans from both stages.
Additionally, our results suggest this association may extend to non-diabetics with high insulin concentrations.
Rarity of the Enh2 risk genotype among African Americans precludes any definitive conclusions, although data
suggest a risk-enhancing role.
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Glucose transporter 1(GLUT1) is the major facilitative
glucose transporter in glomerular mesangial cells [1].
Studies show glucose transport as the rate limiting step
in mesangial expansion, and alterations of GLUT1 activ-
ity may stimulate extracellular matrix(ECM) production
[2] even under normoglycemic conditions [3]. Addition-
ally, experimental evidence suggests GLUT1 may be
associated with hypertensive glomerulopathy [4].
However, results of case-control studies of GLUT1
sequenece variations(the XbaI polymorphism, a C-to-A
transversion in intron 2: see figure 1) and diabetic
nephropathy have been inconsistent [5-11] with signifi-
cant heterogeneity between studies [12]. Most studies
demonstrated risk transmitted in a recessive fashion
[5,6,8,11,13]. Few studies examined diabetic nephropathy
in relation to GLUT1 SNPs other than XbaI [5,11,13].
A study of those with type 1 diabetes examined six
GLUT1 single nucleotide polymorphisms(SNPs) and
found homozygosity for the XbaI A allele was associated
with diabetic nephropathy [5]. Additionally, putative
human enhancer elements were identified [5], including
the insulin-responsive enhancer-2(see figure 1), and
homozygosity for the minor allele(C-to-T) of the enhan-
cer-2 SNP1(Enh2 SNP) was also associated with type 1
diabetic nephropathy [5]. Though Enh2 SNP has strong
linkage disequilibrium with XbaI SNP, more evidence
suggests Enh2 SNP may be causally related to diabetic
nephropathy [5]. More recently, a study extended the
significant association of the Enh2 SNP risk genotype to
those with type 2 diabetic nephropathy; however, a sta-
tistically significant association between XbaI genotypes
and type 2 diabetic nephropathy was not demonstrated
[11].
There has been no investigation among non-diabetics
or African Americans of albuminuria and GLUT1
genetic variation, especially for the Enh2 SNP. Addition-
ally, the Enh2 SNP is not readily available on most can-
didate gene chips, with available proxy SNPs having low
r
2. We conducted a case-control study nested within a
large biracial community-based middle-aged cohort to
determine the risk of albuminuria associated with six
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymorphism [dbSNP ID]  Region  Nucleotide 
Position 
European Americans 
(%Wildtype)/(Heterozygous)/(Homozygous) 
African Americans 
(%Wildtype)/(Heterozygous)/(Homozygous) 
Promoter SNP [rs841839], A>C  Promoter  -5583 
Ctl n=1534: (19.2)/ (48.8)/ (32.1) p=0.31
† 
Cas n=145: (19.3)/ (54.5)/ (26.2) 
Ctl n=922: (33.4)/ (43.0)/ (23.6)    p=0.09
† 
Cas n=136: (35.3)/ (49.3)/ (15.4) 
Intron-1 SNP 1  [rs3768043], A>C  Intron 1  5147 
Ctl n=1521: (58.8)/ (35.5)/ (5.7)   p=0.41
† 
Cas n=148: (54.7)/ (37.2)/ (8.1) 
Ctl n=920: (13.0)/ (45.3)/ (41.6)    p=0.14
† 
Cas n=140: (9.3)/ (40.7)/ (50.0) 
Intron-1 SNP 2  [rs2297977], C>A  Intron 1  9213 
Ctl n=1609: (63.2)/ (32.8)/ (4.0)   p=0.80
† 
Cas n=155: (62.6)/ (32.3)/ (5.2) 
Ctl n=973: (58.8)/ (35.3)/ (6.0)      p=0.85
† 
Cas n=144: (56.3)/ (37.5)/ (6.3) 
Enhancer 2 (Enh2) SNP [rs841847], 
C>T  Intron 2  21793 
Ctl n=1646: (55.7)/ (39.0)/ (5.3)   p=0.08 
Cas n=157: (56.1)/ (34.4)/ (9.6) 
Ctl n=987: (86.9)/ (12.8)/ (0.3)      p=0.78 
Cas n=148: (87.8)/ (12.2)/ (0.0) 
XbaI SNP [rs841853], C>A  Intron 2  23063 
Ctl n=1214: (52.3)/ (42.0)/ (5.7)   p=0.08
† 
Cas n=132: (51.5)/ (37.9)/ (10.6) 
Ctl n=844: (33.0)/ (49.4)/ (17.7)    p=0.49
† 
Cas n=132: (35.6)/ (43.9)/ (20.5) 
Intron-2 SNP [rs841858], C>A  Intron 2  25334 
Ctl n=1574: (68.4)/ (29.0)/ (2.5)   p=0.85
† 
Cas n=153: (68.6)/ (28.1)/ (3.3) 
Ctl n=964: (78.6)/ (20.2)/ (1.2)      p=0.26
† 
Cas n=142: (74.7)/ (22.6)/ (2.8) 
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Figure 1 GLUT1 is located on chromosome 1p34.2.T h eg e n o m i cs t r u c t u r eo fGLUT1 is illustrated with its 10 exons and three putative
enhancers[5]. Genotyped polymorphisms located in intron 2 include the intron-2 SNP (rs841858), and the Enh2(rs841847) and XbaI (rs841853)
SNPs which have been previously associated with diabetic nephropathy[5-7]. In the distal promoter region, the Promoter SNP (rs841839) was
genotyped (located between putative enhancers 3 and 1). We also included two SNPs in intron 1, intron-1 SNP(rs3768043) and intron-2 SNP
(rs2297977). No SNP was associated with albuminuria among all African Americans or among all European Americans, including XbaI (p = 0.08)
and Enh2 (p = 0.08). None of the tagging SNPs were able to reach a Bonferroni adjusted level of statistical significance.
†Bonferroni corrected
level of statistical significance p = 0.01.
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performed a two-stage analysis in our population(n =
10,278): 1) an initial evaluation of all six candidate
GLUT1 SNPs among stage 1 participants(n = 2938), and
2) a subsequent phase (stage 2, n = 7340) to assess the
likeliest stage 1 candidate SNP. Because enhancer-2 is a
putative insulin-responsive element [5], we hypothesized
insulin may interact with the Enh2 SNP to affect risk of
albuminuria.
Methods
Study Design and Population
The study population consisted of African Americans
and European Americans with and without type 2 dia-
betes in the Atheroslcerosis Risk in Communities
(ARIC) Study, aged 45 to 64 years at baseline in 1987
through 1989, from 4 US communities: Forsyth County,
NC; Jackson, MS; suburbs of Minneapolis, MN, and
Washington Co., MD. Participants underwent four stan-
dardized examinations in field center clinics, scheduled
approximately every three years [14] with approval of
the institutional review boards.
Of the 11,625 African American and European Ameri-
can participants who attended visit four, urinary albu-
min and creatinine measurements were available for
11,447 participants. All measurements were from ARIC
visit 4, as urine samples were only collected at this visit.
We excluded those missing visit 4 serum creatinine (n =
182), information on diabetes, hypertension, systolic
blood pressure (SBP), diastolic blood pressure (DBP), or
body mass index (BMI) (n = 125), and those without
available DNA (n = 69). For stage 1, we genotyped six
GLUT1 SNPs (including Enh2 and XbaI) in a sample of
the above participants (sample 1, n = 3,204), enriched
for African Americans and people with type 2 diabetes,
a convenience sample previously used for the study of
genetic risk factors in cardiovascular disease and type 2
diabetes. Sample 1 was an otherwise unselected portion
of the total population. We genotyped only the most
likely candidate SNP (Enh2) from stage 1 in the remain-
ing participants who met our inclusion criteria from
ARIC visit 4, individuals who comprised stage 2 (sample
2, n = 7,867). Missing genotypes were excluded from
stages 1(n = 266) and 2(n = 527). With exclusion cri-
teria, of the total study population (n = 10,278), sample
1(n = 2938) was 28.6% and sample 2(n = 7340) was
71.4%. Participants from samples 1 and 2 were mutually
exclusive.
Of those who attended visit 4, the 1,347 excluded
individuals were older (63.1 vs. 62.8 years of age), more
likely to be African American (37.7% vs. 21.0%), type 2
diabetic (22.5% vs. 16.2%), hypertensive (57.2% vs.
46.7%), and male (46.5% vs. 43.8%) compared to
included participants.
Assessment of Clinical Characteristics
Clinical charcteristics were assessed during visit 4.
A standardized interview, clinical examination, and
laboratory investigation collected demographic, anthro-
pometric, and cardiovascular risk factor data for parti-
cipants [15]. Fasting blood sample collection and
processing is described elsewhere [15]. Two standar-
dized blood pressure measurements were performed by
trained technicians, and their average was used. Hyper-
tension was defined as a systolic blood pressure (SBP)
≥140 mmHg, a diastolic blood pressure (DBP) ≥90
mmHg, or the self-reported use of antihypertensive
medication during the previous 2 weeks. Diabetes melli-
tus was defined as fasting glucose ≥ 126 mg/dL, nonfast-
ing glucose ≥200 mg/dL, or self-reported history or
treatment of type 2 diabetes. Visit 4 glomerular filtration
rate (GFR) was estimated from calibrated serum creati-
nine using the simplified equation developed using data
from the Modification of Diet in Renal Disease (MDRD)
Study [16,17] as follows:
GFR mL/min/1.73m
2 =1 8 6 . 3*( S C r )
-1.154 * (age)
-0.203
* (0.742 if female) * (1.21 if African American)
Ascertainment of Albuminuria
An untimed urine sample was collected during visit
4. Aliquots were frozen within 12 hours and stored at
-70°C. Albumin and creatinine concentrations were
measured in the University of Minnesota Physicians
Outreach Laboratories, Minneapolis, Minnesota, with
albumin by a nephelometric method on the Dade Behr-
ing BN100 (assay sensitivity, 2.0 mg/L), and creatinine
using the Jaffe method on a Beckman CX3 to determine
albumin-to-creatinine ratios (ACR; ug/mg) for partici-
pants. Blinded samples (n = 516) analyzed for quality
assurance showed a correlation coefficient
® of the loge-
transformed ACR as r = 0.95. ACR was used to deter-
mine levels of albuminuria according to American
Diabetes Association [18] and National Kidney Founda-
tion [19] recommendations: normoalbuminuria (ACR <
30 μg/mg), microalbuminuria (ACR 30-299 μg/mg), and
macroalbuminuria (ACR ≥ 300 μg/mg). Normoalbuminu-
ric participants were classified as controls. Albuminuria
cases had either microalbuminuria or macroalbuminuria.
Of the total study, there were 825 cases of albuminuria,
37.0%(n = 305) in sample 1 and 63.0%(n = 520) in sample
2. For sensitivity analysis, microalbuminuria and macroal-
buminuria cases were examined separately, compared to
controls.
GLUT1 Candidate SNP Selection and Genotyping
GLUT1 consists of 10 exons including three recently
described putative human enhancers (see Figure 1) [5]
with murine and rat homology [20,21]. The XbaI SNP
[5-7] and the Enh2 SNP [5,11] were chosen as
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Using the human GLUT1 genomic sequence(GenBank
accession no. NT_032977) and the public SNP database
dbSNP build 120, it was determined the XbaI SNP cor-
responds to rs841853 and the Enh2 SNP corresponds to
rs841847. The dbSNP rs841839 C > A transversion
(denoted Promoter SNP) was chosen for genotyping
based on its proximity to both enhancers-3 and -1. At
the time of genotyping, the Hap Map Phase II data were
not available; therefore, 3 additional SNPs were chosen
with an average distance between SNPs of 4.2 kb to pro-
vide coverage of the gene (76.8%). Three additional
SNPs selected were: intron-1 SNP1(rs3768043), intron-1
SNP2(rs2297977), and intron-2 SNP(rs841858).
For the evaluation phase, genotypes in sample 1 were
assessed by PCR amplification of genomic DNA and
completed for rs841847(Enh2 SNP) using Pyrosequen-
cing technology (Pyrosequencing, Uppsala, Sweden) as
previously described [22]. For the SNPs rs841853 (XbaI),
rs841839, rs3768043, rs2297977, and rs841858, geno-
types were completed using Orchid SNPstream UHT
genotyping system (Orchid Bioscience) as previously
described [23]. For sample 1, the error rate on the basis
of blind replicates (n = 444) for the Orchid SNPstream
UHT genotyping system was 0.2%. For the replication
phase, genotypes for rs841847 in sample 2 were assessed
and completed using Pyrosequencing technology.
Statistical Analysis
For stage 1(n = 2938), genotype frequencies of all SNPs
were tested for consistency with Hardy-Weinberg expec-
tations by the c
2 test within race strata among controls
consisting of non-diabetic individuals without albumi-
nuria. Because allele frequencies differed by race, ana-
lyses were race-stratified. Tests of differences in clinical
characteristics by case status included t-tests, ANOVA,
and c
2 tests. Logistic regression models calculated the
odds ratio (OR) and 95% confidence interval (95% CI)
of albuminuria for each SNP, using either genotypic or
recessive models for inheritance. Our genotypic associa-
tions of XbaI and Enh2 in European Americans suggest
recessive modes of action, similar to previous findings
[5,6]. To differentiate the effects of the likely candidate
from remaining GLUT1 SNPs, multivariate logistic
regression was performed, adjusting for type 2 diabetes,
XbaI, Enh2, rs841839, rs841858, rs2297977, and
rs3768043 genotypes.
There was strong prior evidence for Enh2 (rs841847)
as a functional candidate polymorphism, both in human
and laboratory studies [5,11,24-29]. Based on this a
priori determination of the status of Enh2 (rs841847) as
a functional candidate SNP, we believed it was appropri-
ate to keep the alpha for statistical significance of p <
0.05 for analyses focusing on Enh2 (rs841847) with
further correction. However, given that the other 5
SNPs (rs841853, rs841839, rs3768043, rs2297977,
rs841858) examined were largely meant to be tagging
SNPs without any prior evidence to suggest function, we
felt it necessary to correct for multiple testing errors by
applying a Bonferroni correction [30], with the corrected
alpha for statistical significance at the 0.05 level deter-
mined by dividing the significance level by the number
of tagging SNPs, with adjusted p-value < 0.01.
Using the Bayesian method as implemented in PHASE
v2.1 [31,32], haplotypes were inferred for all individuals
with genotype data for at least five of the six SNPs
(rs841847, rs841853, rs841839, rs3768043, rs2297977,
rs841858) separately for African Americans (n = 1,036)
and European Americans (n = 1638). Phase-formatted
data were run as race-specific files which combined case
and control subjects, a more conservative estimation of
haplotype frequency than separate case and control
sample analyses. Pairwise SNP linkage disequilibrium
(LD) was measured with D’ and r
2 [33] in HaploView
(Cambridge, MA). Categorized by major haplotypes (>
5% frequency), haplotype frequency was compared
between case and control groups with c
2 test. For hap-
lotype analyses, a Bonferroni correction was also applied
by dividing the significance level (0.05) by the number
of major haplotypes (n = 4 for European Americans, n =
8 for African Americans) for haplotype-based associa-
tion analysis (Bonferroni corrected level of statistical sig-
nificance for European Americans p < 0.0125, for
African Americans p < 0.00625). Associations with albu-
minuria for each diplotype (of major haplotypes) were
examined separately using logistic regression. For diplo-
type analyses for European Americans, a Bonferroni cor-
rection was also applied by dividing the significance
level by the number of diplotypes (n = 10) comprised of
the major haplotypes, with adjusted level of statistical
significance p < 0.005.
In stage 2 (n = 7340) the Enh2 SNP was genotyped.
Associations of albuminuria/microabluminuria/macroal-
b u m i n u r i aa n dt h eE n h 2r i s kg e n o t y p ew e r ea s s e s s e d
using multivariate logistic regression models for the
total study population, stratified by race and type 2 dia-
betes. Covariates included age, gender, systolic blood
pressure, diastolic blood pressure, hypertension medica-
tion use, BMI, estimated GFR, and fasting glucose.
Additionally, among non-diabetics, we examined inter-
actions of albuminuria/macroalbuminuria for the Enh2
risk genotype with quartiles of fasting insulin, based on
the Enh2 SNP location in the putative insulin-responsive
enhancer 2 [5]. Multivariate linear regression was used
to assess associations between the Enh2 risk genotype
with log-transformed ACR μg/mg (data log-transformed
due to the skewed distribution) and also serum creati-
nine among European Americans, stratified by type 2
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can Americans due to the rarity of the Enh2 risk geno-
type in that population.
Results
GLUT1 SNPs
Six SNPs (average spacing 4.2 kb) of the GLUT1 geno-
mic region (Promoter SNP, Intron-1 SNPs 1 and 2,
Enhancer 2 SNP, XbaI SNP, and Intron 2 SNP) were
genotyped in an unrelated sample of 1803 European
Americans and 1135 African Americans in stage 1
(Figure 1). In European Americans, all SNPs were in
Hardy-Weinberg Equilibrium (HWE). Among African
Americans, the Promoter SNP was not in HWE (P <
0.05). XbaI minor allele(A) frequency in African Ameri-
cans was higher than in European Americans (frequency =
0.42 versus 0.27). In European Americans, the XbaI A
allele and the Enh2 T allele (frequency = 0.25) were com-
p a r a b l et op r e v i o u s l yp u b l i s h ed estimates [5,6,8,9,11].
However, minor allele of Enh2(T) was low in African
Americans (frequency = 0.07).
The five SNPs (Intron-1 SNPs 1 and 2, Enh2 SNP,
XbaI SNP, and Intron-2 SNP) downstream of Promoter
SNP were in strong LD with each other (range of D’ =
0.95 to 1.00 in European Americans and 0.96 to 1.00 in
African Americans) [34]. The promoter SNP was sepa-
rated from Intron-1 SNP1 by ~10 kb and was in greater
LD among European Americans (D’ =0 . 6 9 )t h a nA f r i -
can Americans (D’ = 0.09). Among both African Ameri-
cans and European Americans, Enh2 and XbaI SNPs
were in strong LD (D’ = 0.96); however, the r
2was much
lower in African Americans compared to European
Americans (0.09 vs. 0.70) because frequencies of Enh2
and XbaI significantly differed in African Americans.
Clinical Characteristics
In both race groups in stage 1, the case subjects had
worse risk factor profiles than controls (Table 1). Risk
factor profiles were also worse for case subjects among
participants from stage 2 (n = 7340).
Stage 1: Evaluation Phase of Six GLUT1 SNP Genotypes
by Albuminuria Case Status
European Americans
Among European Americans in stage 1, GLUT1 SNP
genotype distributions were not significantly different by
case status, though the Enh2 SNP approached statistical
significance (P = 0.08, figure 1). XbaI and other tagging
SNPs did not approach the Bonferroni corrected level of
statistical significance of p < 0.01. For Enh2 T allele,
heterozygotes had an OR = 0.88, while homozygotes
had OR = 1.77 (95% CI: 0.98 - 3.20). Similarly for the
XbaI A allele, heterozygotes had OR 0.92 while homozy-
gotes had OR 1.89 (95% CI: 1.01 - 3.55). Our genotypic
associations of XbaI and Enh2 in European Americans
suggest a recessive model, similar to previous findings
[5,6,11].
Albuminuria was associated with the Enh2 TT risk
genotype with OR 2.36 (95% CI: 1.09 - 5.09, P = 0.025)
compared to those without the risk genotype (CC or
CT) among those with type 2 diabetes. This association
was not present among non-diabetics (OR 1.31, P =
0.574, Table 2). Similarly, the XbaI risk genotype (AA)
had a larger association with albuminuria among those
with type 2 diabetes rather than non-diabetics (OR 2.23
[P = 0.064] and 1.75 [P = 0.212], respectively), though
associations were not statistically significant for XbaI
and did not approach the Bonferroni corrected level of
statistical significance (p < 0.01) (Table 2). Among Eur-
opean Americans stratified by diabetes, besides Enh2 no
other GLUT1 polymorphisms were associated with albu-
minuria (results not shown). In all European Americans,
multivariate analysis adjusting for diabetes simulta-
neously examined the association with albuminuria of
all six GLUT1 SNPs, and the Enh2 risk genotype had an
increased OR with albuminuria (OR = 3.37, 95% CI:
0.83 - 13.78, p = 0.090) whereas XbaI did not (OR =
0.94, 95% CI: 0.26-3.42, p = 0.931). For the four remain-
ing SNPs, genotypic ORs ranged from 0.72 to 1.85 (all
p-values > 0.17) with none of the SNPs approaching the
Bonferroni adjusted statistical significance level of
p < 0.01.
Similarly, detailed haplotype and diplotype analyses
supported a potential role of the Enh2 TT genotype in
raising the risk of albuminuria in a recessive fashion
(Table 3). When the ten diplotypes associated with the
m a j o rh a p l o t y p e sA ,B ,C ,a n dD( t a b l e3 )w e r ee x a m -
ined among European Americans, only the BD diplotype
was associated with albuminuria (OR 3.03, 95% CI 1.36
- 6.79, p = 0.007, compared to individuals without the
BD diplotype). However, this approached but did not
reach a Bonferroni corrected level of statistical signifi-
cance of p < 0.005. Additionally, the diplotypes consist-
i n go ft h eBo rD“risk” haplotypes were rare among
European Americans, with BB, BD, and DD diplotypes
accounting for 2.7%, 2.2%, and 0.5% of the 1663
European Americans with available diplotypes analyzed.
Overall, haplotype diplotypes homozygous for the Enh2
T allele had an increased risk of albuminuria compared
to all others combined (P = 0.014), though it did not
reach the Bonferroni corrected level of statistical signifi-
cance of p < 0.005.
African Americans
Among African Americans, no GLUT1 SNP was signifi-
cantly associated with case status. Frequency of the Pro-
moter SNP genotype was slightly but not significantly
different by case status (see figure 1). Enh2 TT genotype
was rare (0.3% in controls, 0.0% in cases) and did not
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power to examine the XbaI SNP (with the minor A
allele frequency of 42.4%) and case status in African
Americans, which was not significant(P = 0.5). By dia-
betes status, the XbaI AA risk genotype was not asso-
ciated with albuminuria either among those with type 2
diabetes (OR 1.05, 95% CI: 0.53 - 2.09) or without dia-
betes (OR 1.34, 95% CI: 0.70 - 2.56). Further detailed
haplotype and diplotype analyses did not demonstrate
any significant associations with albuminuria among
African Americans (P = 0.877, table 3).
GLUT1 Enh2 and Albuminuria in Samples from Stages 1
and 2
Based on stage 1, the Enh2 SNP appeared to be the risk
polymorphism affecting albuminuria, particularly among
European Americans with type 2 diabetes. The GLUT1
Enh2 polymorphism was genotyped in a separate stage 2
of European Americans (n = 6319; 374 cases) and
African Americans (n = 1021, 146 cases), and the risk
genotype tended towards an increased (but not statisti-
cally significant) OR among European Americans with
diabetes (OR = 1.66, 95% CI: 0.77 - 3.57, p = 0.192) but
not among non-diabetics (OR = 0.99, 95% CI: 0.61 -
1.59, p = 0.953). The risk association among European
Americans with diabetes from stage 1 was not replicated
in stage 2. In the stage 2 sample of African Americans,
the GLUT1 Enh2 risk genotype was still rare (0.1% of
controls and 1.4% of cases, Chi-square(2d.f.) P = 0.03)
precluding informative analysis by diabetes status.
By race, we combined the samples from stages 1 and 2
for European Americans (n = 8,122) and African Ameri-
cans (n = 2156) and examined risk-factor adjusted asso-
ciations with albuminuria and the GLUT1 Enh2 risk
genotype by diabetes status (Table 4). Among European
Americans with diabetes, the Enh2 risk genotype had an
increased risk-factor adjusted OR with albuminuria (OR
2.11, p = 0.010), microalbuminuria (OR 2.01, p = 0.034)
Table 1 Baseline Characteristics. Clinical characteristics of study subjects by Race and Albuminuric Status
Stage 1 Stage 2
European Americans (n = 1803) European Americans (n = 6319)
Characteristic Control Subjects Albuminuria Cases Control Subjects Albuminuria Cases
N 1646 157 5945 374
Age, mean(SD), y 63.2 (5.6) 64.9 (5.6)*** 62.8 (5.6) 65.2 (5.6)***
Male, No. (%) 802 (48.7) 92 (58.6)* 2655 (44.7) 199 (53.2)**
Hypertension, No. (%) 731 (44.4) 111 (70.7)*** 2266 (38.1) 269 (71.9)***
Type 2 Diabetes, No. (%) 480 (29.2) 84 (53.5)*** 428 (7.2) 103 (27.5)***
Body mass index, kg/m
2 29.0 (5.5) 30.0 (6.3)* 28.0 (5.0) 28.8 (6.0)**
SBP (mmHg) 126.8 (17.4) 135.7 (20.4)*** 124.4 (17.8) 138.3 (23.2)***
DBP (mmgHg) 69.7 (10.0) 70.0 (11.1) 69.5 (9.6) 72.5 (12.1)***
Fasting Glucose (mg/dL)
§ 115.4 (34.9) 134.4 (52.2)*** 102.1 (21.2) 116.8 (43.4)***
GFR, ml/min per 1.73 m2 81.7 (16.9) 75.0 (25.7)*** 80.7 (16.1) 76.1 (22.3)***
ACR, μg/mg, median (25%ile, 75%ile) 3.7 (1.8,6.7) 102.6 (47.4,275.0)*** 3.6 (2.0,6.5) 74.8 (44.4,166.7)***
African Americans (n = 1135) African Americans (n = 1021)
Characteristic Control Subjects Albuminuria Cases Control Subjects Albuminuria Cases
N 987 148 875 146
Age, mean(SD), y 61.3 (5.5) 63.0 (5.8)
††† 61.8 (5.7) 62.5 (5.7)
Male, No. (%) 336 (34.0) 44 (29.7) 324 (37.0) 54 (37.0)
Hypertension, No. (%) 615 (62.3) 127 (85.8)
††† 558 (63.8) 127 (87.0)
†††
Type 2 Diabetes, No. (%) 217 (22.0) 80 (54.1)
††† 196 (22.4) 80 (54.8)
†††
Body mass index, kg/m
2 30.7 (6.5) 30.8 (6.6) 30.3 (5.9) 31.4 (6.6)
†
SBP (mmHg) 131.2 (18.4) 144.4 (23.2)
††† 132.0 (18.9) 144.8 (22.5)
†††
DBP (mmgHg) 75.0 (10.0) 78.2 (13.0)
††† 75.7 (10.1) 78.5 (11.9)
††
Fasting Glucose (mg/dL)
§ 114.3 (39.6) 136.4 (62.2)
††† 112.7 (38.5) 137.9 (62.8)
†††
GFR, ml/min per 1.73 m2 91.5 (19.0) 83.0 (29.8)
††† 90.9 (21.0) 80.7 (29.3)
†††
ACR, μg/mg, median (25%ile, 75%ile) 1.9 (0.7,4.7) 95.9 (47.2,363.2)
††† 2.2 (0.8,5.2) 81.7 (44.7,249.7)
†††
Data are means (SD), number (%), or for ACR median (25%ile, 75%ile). European Americans: * P < 0.05; **P < 0.01; ***P < 0.001.
African Americans: †P < 0.05; ††P < 0.01; †††P < 0.001.
§Individuals with fasting glucose measured. Evaluation set (European Americans n = 1582 controls and n = 150 cases; African Americans n = 922 controls and n
= 113 cases). Valdiation set (European Americans n = 5822 controls and n = 356 cases; African Americans n = 787 controls and n = 113 cases).
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Page 6 of 13Table 2 Stage 1GLUT1 Enh2 and XbaI Risk genotype distributions among case and control subjects and odds ratio of
albuminuria, by diabetes and race
European Americans
Type 2 Diabetes No Type 2 Diabetes
SNP Controls Cases P-value OR (95% CI) Controls Cases P-value OR (95% CI)
Enh2 SNP (C > T) 480 84 1166 73
CC or CT (94.6) (88.1) 0.025 1.00 (94.7) (93.1) 0.574 1.00
TT (5.4) (11.9) 2.36 (1.09 - 5.09)* (5.3) (6.9) 1.31 (0.51 - 3.36)
XbaI SNP (C > A)
† 348 70 866 62
CC or CA (94.5) (88.6) 0.064 1.00 (94.2) (90.3) 0.212 1.00
AA (5.5) (11.4) 2.23 (0.94 - 5.33) (5.8) (9.7) 1.75 (0.72 - 4.25)
African Americans
Type 2 Diabetes No Type 2 Diabetes
SNP Controls Cases P-value OR (95% CI) Controls Cases P-value OR (95% CI)
Enh2 SNP (C > T) 217 80 770 68
CC or CT (99.5) (100.0) 0.543 1.00 (99.7) (100.0) 0.674 1.00
TT (0.5) (0.0) N/A (0.3) (0.0) N/A
XbaI SNP (C > A)
† 190 73 654 59
CC or CA (81.6) (80.8) 0.888 1.00 (82.6) (78.0) 0.376 1.00
AA (18.4) (19.2) 1.05 (0.53 - 2.09) (17.4) (22.0) 1.34 (0.70 - 2.56)
*P < 0.05.
†Bonferroni correction requires p < 0.01 to reach statistical significance.
Table 3 Major Haplotype Distribution in Case and Control Subjects by Race in stage 1
†‡
European
Americans
Haplotype Promoter
SNP
Intron-1
SNP1
Intron-1
SNP2
Enh2
SNP
XbaI
SNP
Intron-2
SNP
Controls Albuminuria
Cases
P-
value
N = 3326
Haplotypes
A C A C C C C (43.4) (39.5) 0.773
B A A C T A C (17.2) (18.9)
C A C A C C A (14.1) (14.5)
D C A C T A C (6.2) (6.8)
Others * * * * * * (19.1) (20.3)
African Americans
N = 2156
Haplotypes
A C A C C C C (13.7) (10.7) 0.877
B A A C T A C (5.4) (5.0)
C A C A C C A (7.7) (9.6)
E C C C C C C (14.0) (13.9)
F C C C C A C (11.0) (12.1)
G A C C C A C (12.7) (11.4)
H A C A C C C (11.9) (12.1)
I A A C C A C (6.8) (7.5)
Others * * * * * * (16.8) (17.5)
‡ Major haplotypes have a frequency ≥ 5%. Minor alleles are shaded in gray. Bonferroni corrected level of statistical significance for European Americans p <
0.0125 and for African Americans p < 0.00625.
† Among European Americans, the ten diplotypes associated with the major haplotypes A, B, C, and D from table 3, only the BD diplotype was associated with
albuminuria (OR 3.03, 95% CI 1.36 - 6.79, p = 0.007, compared to individuals without the BD diplotype). However, this did not reach a Bonferroni corrected level
of statistical significance of p < 0.005. The diplotypes consisting of the B or D “risk” haplotypes were rare, with BB, BD, and DD diplotypes accounting for 2.7%,
2.2%, and 0.5% of the 1663 European Americans with available diplotypes analyzed.
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Page 7 of 13and macroalbuminuria (OR 2.69, p = 0.045) (Model 1,
Table 4). Further adjustment for BMI and estimated
r e n a lf u n c t i o n( m o d e l2 )d i dn o t significantly affect the
associations (with albuminuria OR 2.14, p = 0.009), nor
did further adjustment for fasting glucose (OR 1.99, p =
0.029). However, among European Americans without
type 2 diabetes, Enh2 was not associated with albumi-
nuria (OR 1.01, p = 0.980) and was moderately but not
significantly associated with macroalbuminuria (OR
1.64, 95% CI: 0.64-4.25, p = 0.305) (Model 1, Table 4).
Additional adjustment for visit 2 hemoglobin A1C
(HbA1C) in a sub-sample did not significantly change
point estimates with albuminuria (OR = 1.87, 95% CI:
1.02 - 3.42 in diabetic individuals, OR = 1.25, 95% CI:
0.63 - 2.46 in non-diabetics). There was no evidence of
interaction with hypertension (results not shown). Addi-
tionally, among European Americans, we also examined
potential associations using multivariate linear
regression with log-transformed ACR μg/mg (data log-
transformed due to the skewed distribution) and also
serum creatinine among European Americans, stratified
by type 2 diabetes (see Table 5). Though the Enh2 risk
genotype tended to be positively associated with worse
ACR and higher serum creatinine only among type 2
diabetic European Americans, there were no statistically
significant associations. We did not perform this analysis
among African Americans given the low frequency of
the Enh2 risk genotype among this population.
Among African Americans, after adjustment for model
2 covariates, the GLUT1 Enh2 risk genotype had a posi-
tive association with albuminuria and microalbuminuria
among those with type 2 diabetes (OR = 4.36 and 6.39
with p = 0.321 and 0.203, respectively) and without dia-
betes (OR = 4.69 and 5.15 with p = 0.187 and 0.164,
respectively), though it was not significant due to low
frequency of the SNP.
Table 4 Adjusted relative odds of albuminuria, microalbuminuria, and macroalbuminuria for Enh 2 in all genotyped
European Americans and African Americans, by type 2 diabetes status
GLUT1 Enh2 Risk Genotype(TT) Relative Odds (95% Confidence Interval) reference:
(CC or CT)
Model
† (N = Enh2 TT Genotype/All Genotypes) ALBUMINURIA (N Cases =
Cases with Enh2 TT
Genotype/All Cases)
MICROALBUMINURIA (N
Cases = Cases with Enh2 TT
Genotype/All Cases)
MACROALBUMINURIA (N
Cases = Cases with Enh2 TT
Genotype/All Cases)
EUROPEAN AMERICANS OR (95% CI) P-Value OR (95% CI) P-Value OR (95% CI) P-Value
TYPE 2 DIABETES (N = 72/1,095) (N Cases = 20/187) (N Cases = 14/134) (N Cases = 6/53)
Model 1 2.11 (1.19 - 3.73) * 0.010 2.01 (1.06 - 3.82) * 0.034 2.69 (1.02 - 7.09) * 0.045
Model 2 2.14 (1.20 - 3.80) ** 0.009 2.00 (1.05 - 3.81) * 0.035 2.66 (0.98 - 7.26) 0.056
Model 2 + Fasting Glucose
§ 1.99 (1.07 - 3.68) * 0.029 2.07 (1.06 - 4.06) * 0.034 1.85 (0.58 - 5.91) 0.299
NON-DIABETIC (N = 478/7,027) (N Cases = 24/344) (N Cases = 19/298) (N Cases = 5/46)
Model 1 1.01 (0.65 - 1.55) 0.980 0.91 (0.56 - 1.48) 0.713 1.64 (0.64 - 4.25) 0.305
Model 2 1.03 (0.67 - 1.59) 0.899 0.93 (0.57 - 1.50) 0.764 1.77 (0.67 - 4.64) 0.246
Model 2 + Fasting Glucose
§ 1.05 (0.68 - 1.63) 0.815 0.95 (0.59 - 1.54) 0.843 1.78 (0.68 - 4.66) 0.242
AFRICAN AMERCIANS OR (95% CI) P-Value OR (95% CI) P-Value
TYPE 2 DIABETES (N = 2/573) (N Cases = 1/160) (N Cases = 1/107) (N Cases = 0/53)
Model 1 3.09 (0.18 - 54.14) 0.440 5.37 (0.32 - 90.91) 0.244
Model 2 4.36 (0.24 - 79.81) 0.321 6.39 (0.37 - 110.75) 0.203
Model 2 + Fasting Glucose
§ 7.26 (0.38 - 137.93) 0.187 8.12 (0.44 - 148.09) 0.158
NON-DIABETIC (N = 4/1583) (N Cases = 1/134) (N Cases = 1/113) (N Cases = 0/21)
Model 1 3.29 (0.33 - 32.84) 0.310 4.14 (0.41 - 41.44) 0.227
Model 2 4.69 (0.47 - 46.58) 0.187 5.15 (0.51 - 51.66) 0.164
Model 2 + Fasting Glucose 8.07 (0.70 - 93.63) 0.095 8.60 (0.73 - 100.97) 0.087
Statistical significance of point estimates: * P < .05 | ** P < .01 | *** P < .001.
† Analyses with microalbuminuria as the outcome excluded macroalbuminuria cases. Analyses with macroalbuminuria as the outcome excluded microalbuminuria
cases. Among African Americans, analyses with macroalbuminuria were omitted due to extremely low allele frequency.
Model 1 includes age, sex, systolic blood pressure, diastolic blood pressure and hypertension medication use.
Model 2 includes Model 1 covariates and BMI and estimated glomerular filtration rate.
§ Model 2 + Fasting Glucose is limited to individuals with fasting glucose values: non-diabetic European Americans N = 6,927 (340 albuminuria cases) and
European Americans with type 2 diabetes N = 983 (166 albuminuria cases) and non-diabetic blacks N = 1,520 (126 albuminuria cases) and blacks with type 2
diabetes N = 415 (100 albuminuria cases).
Among European Americans, P-values estimating interaction between GLUT Enh2 and diabetes were not significant for the outcomes of albuminuria
(P-interaction = 0.064), microalbuminuria (P-interaction = 0.071), and macroalbuminuria (P-interaction = 0.730). Among blacks, P-values estimating interaction
between GLUT Enh2 and diabetes were not significant for the outcomes of albuminuria (P-interaction = 0.86), microalbuminuria (P-interaction = 0.96).
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Page 8 of 13The GLUT1 Enh2 Risk Genotype and Insulin
To examine effects of insulin concentration on the asso-
ciation of GLUT1 Enh2 genotypes and albuminuria, we
stratified by insulin concentrations excluding those with
diabetes (to avoid confounding due to insulin treatment
for diabetes). Due to the low frequency of the GLUT1
Enh2 risk genotype among African Americans, analysis
was limited to European Americans. Among European
Americans, (n = 6583 controls, 294 cases of microalbu-
minuria, and 46 cases of macroalbuminuria), the mean
fasting insulin concentration was 10.9 μU/mL (S.D. =
7.5). Risk of albuminuria for Enh2 TT was OR 1.08
(95% CI: 0.70 - 1.67, p = 0.724), adjusting for age, gen-
der, hypertension status, BMI, and GFR. Among indivi-
duals with insulin in the highest quartile (mean insulin
19.9 μU/mL, S.D. = 9.7), the adjusted OR of albuminuria
for Enh2 TT was 1.25 (95% CI: 0.60 - 2.58, p = 0.547).
Among individuals with insulin concentrations in the
lower three quartiles (mean 7.9 μU/mL, S.D. = 2.9), the
adjusted OR of albuminuria was 1.00 (95% CI: 0.58 -
1.72, p = 0.990) for Enh2 TT carriers. When we focused
on the more specific outcome of macroalbuminuria as a
phenotype and excluded patients with microalbumi-
nuria, risk of macroalbuminuria for Enh2 TT was OR
1.84 (95% CI: 0.71 - 4.77, p = 0.210) as illustrated in
figure 2. Among individuals with insulin in the highest
quartile, the adjusted OR for Enh2 TT was 4.08 (95%
CI: 1.06 - 15.61, p = 0.040). Among individuals with
insulin concentrations in the lower three quartiles, the
adjusted OR of macroalbuminuria was 1.00 (95% CI:
0.23 - 4.28; P = 0.995) for Enh2 TT carriers. Among
non-diabetics, a formal test of interaction of the GLUT1
Enh2 risk genotype and the upper quartile of insulin
was not significant for macroalbuminuria (P = 0.163).
Discussion
Genetic variation of GLUT1 may be associated with the
risk of micro- and macroalbuminuria in the general U.S.
adult population of European Americans with type 2
diabetes. Though an association was seen when we com-
bined European Americans with diabetes from stages 1
and 2, the findings of stage 1 were not replicated in
stage 2. Both XbaI and Enh2 SNPs appeared to be asso-
ciated in a recessive fashion with albuminuria, consistent
with previous studies [5,6,8,11,13]. Further analysis
showed Enh2 risk genotype (TT) increased risk indepen-
dent of all other genotyped GLUT1 SNPs, including
XbaI, suggesting that Enh2 is the causative GLUT1 SNP
associated with albuminuria. Addtionally, no other
GLUT1 SNPs besides Enh2 have been demonstrated to
be located in a region with functional activity in vitro
[5,6,8,13]. By study stage, the Enh2 risk genotype was
associated with diabetic albuminuria among European
Americans only in stage 1 and in the total study popula-
tion; these findings were not replicated when we exam-
ined stage 2. In the total study population of European
Americans with type 2 diabetes, the risk effect of Enh2
on macroalbuminuria was independent of age, gender,
and hypertension. Possession of the Enh2 risk genotype
and high insulin concentrations particularly increased
macroalbuminuria risk among non-diabetic European
Americans. Among African Americans, XbaI was not
associated with albuminuria. The association of the
Enh2 risk genotype and albuminuria among African
Americans was increased among individuals with and
without type 2 diabetes but was not statistically signifi-
cant. Despite having over 2000 African Americans in
the present study, the low frequency of the Enh2 risk
genotype in this population (0.3%) limited the power of
our analysis and prevents us from making definitive
conclusions about the role of GLUT1 genetic variation
and albuminuria in African Americans. However, our
results suggest that GLUT1 Enh2 may be associated
with albuminuria.
In European Americans, our results extend the find-
ings of a prior study by Ng et al. among type 1 diabetics
Table 5 Unadjusted and multivariate linear regression of ln (ACR) and serum creatinine for Enh 2 in all genotyped
European Americans, by type 2 diabetes status
Regression coefficient forGLUT1 Enh2 Risk Genotype(TT) (95% CI) reference: (CC or CT)
(N = Enh2 TT Genotype/All Genotypes) ln (ACR) ß Coefficient (95% CI) P-value Serum Creatinine ß Coefficient (95% CI) P-value
TYPE 2 DIABETES (N = 72/1,095)
Unadjusted 0.26 (-0.17 - 0.69) 0.240 0.06 (-0.00 - 0.13) 0.069
Model 1 0.27 (-0.14 - 0.68) 0.196 0.02 (-0.04 - 0.09) 0.446
Model 2 0.28 (-0.13 - 0.68) 0.185 0.02 (-0.04 - 0.09) 0.446
NON-DIABETIC (N = 478/7,027)
Unadjusted -0.02 (-0.12 - 0.09) 0.737 -0.01 (-0.04 - 0.01) 0.189
Model 1 -0.02 (-0.12 - 0.08) 0.702 -0.01 (-0.03 - 0.01) 0.146
Model 2 -0.02 (-0.12 - 0.08) 0.667 -0.01 (-0.03 - 0.00) 0.143
Model 1 includes age, sex, systolic blood pressure, diastolic blood pressure and hypertension medication use.
Model 2 includes Model 1 covariates and BMI and estimated glomerular filtration rate for the outcome ln (ACR). For the outcome of serum creatinine, model 2
includes Model 1 covariates and BMI.
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Page 9 of 13[35], suggesting both XbaI and Enh2 homozygotes as
having an increased risk of albuminuria. However, the
authors could not examine the independent risk effect
of Enh2 or XbaI separately; since no individuals in their
study possessed the Enh2 risk genotype but not the
XbaI risk genotype. Multivariate analysis in our study
suggest the XbaI AA risk genotype by itself does not
confer risk (OR = 0.94, p = 0.931), whereas the Enh2
TT risk genotype (OR = 3.37, p = 0.090) has a stronger
association with albuminuria independent of XbaI.O u r
results extend the risk association of Enh2 to albumi-
nuria in European Americans with type 2 diabetes.
Additionally, a recent study in Tunisia of type 2 dia-
betics had similarly demonstrated an association of the
Enh2 TT risk genotype with nephropathy (OR 8.4 (95%
CI: 3.3-21.5)) while finding no association with XbaI
[11].
Additionally, our results suggest that among non-dia-
betic European Americans with the Enh2 risk genotype,
those with higher concentrations of insulin were at
greater risk of having proteinuria. The putative human
enhancer-2 is homologous with the murine enhancer-2
which was responsive to insulin in vitro [5,24]. Further-
more, the Enh2 SNP is located within a binding site for
the insulin-responsive transcription factor, the upstream
stimulatory factor (USF) [5,25,26]. USF has been identi-
fied as a glucose-inducible transcription factor in mesan-
gial cells [27,28] and shown to regulate GLUT1
transcription [29]. The Enh2 SNP of GLUT1 is located
within a USF responsive element in humans, suggesting
the TT genotype might have altered gene expression of
GLUT1 that contributes to diabetic nephropathy [36].
Additionally, the interaction of the Enh2 SNP and insu-
lin supports the previously posited hypothesis [5] that in
individuals with the Enh2 risk genotype, high intracellu-
lar glucose concentrations might increase in mesangial
cells in response to insulin [37]. The high concentra-
tions of intracellular glucose may contribute to mesan-
gial matrix expansion and glomerulosclerosis through
several pathologic cellular mechanisms including the
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Figure 2 Macroalbuminuria, Enh2 risk genotypes and insulin concentrations among non-diabetic European Americans (n = 6629 (46
cases)). *P < 0.05. Among non-diabetic European Americans with fasting insulin, the risk of macroalbuminuria associated with the GLUT1 Enh2
TT risk genotype was 1.84, 95% CI: 0.71 - 4.77, P = 0.210, adjusting for age, gender, hypertension status, BMI, and GFR. For individuals in the
upper quartile of insulin concentrations, the Enh2 TT genotype was associated with macroalbuminuria (OR 4.08, 95% CI: 1.06 - 15.61, p = 0.040)
while it was not associated among those in the lower three quartiles (OR 1.00, 95% CI: 0.23 - 4.28, P = 0.995). There was no significant
interaction between high concentrations of insulin and Enh2 TT genotypes on macroalbuminuria risk (P-interaction = 0.163).
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Page 10 of 13polyol pathway, activation of protein kinase C, increased
formation of advanced glycation end-products, and the
hexosamine pathway [38,39]. Additionally, there is evi-
dence that podocytes are critical in maintaining the glo-
merular filtration barrier of the kidney and preventing
albuminuria [40-42], and a recent study demonstrated
that the glucose uptake of podocytes are insulin respon-
sive and act via GLUT1, suggesting the insulin sensitivity
of human podocytes resulting in urinary protein loss may
act via these mechanisms [43]. Future studies should
examine if the Enh2 SNP indeed modulates GLUT1 pro-
tein expression. Furthermore, most candidate gene chips
(Affymetrix 5.0, 6.0, 500K, 100K; Illumina 550K, 650K)
do not include Enh2 SNP. This suggests follow-up
studies may need de-novo genotyping.
Previous studies of XbaI and diabetic nephropathy
have had disparate results [12]. Our results for the XbaI
risk genotype in European Americans are consistent
with previous studies which demonstrated increased risk
of type 1 diabetic nephropathy among those homozy-
gous for the XbaI A allele [5,6], suggesting recessive
transmission of the phenotype. Inconsistent results in
other studies of XbaI may be due to different patterns
of disequilibrium with the Enh2 polymorphism [7-11].
Our study has several limitations. Its design is cross-
sectional and the albuminuria classification is based on
a spot urine ACR because urine which was only col-
lected at one ARIC visit. A phenotype based on a single
measurement of ACR could definitely lead to incorrect
conclusions, particularly with potential misclassification
of borderline values with a dichotomous outcome such
as albuminuria. However, sensitivity analyses for macro-
albuminuria demonstrated a significant risk association
with the Enh2 risk genotype. Another limitation is that
the Enh2 risk genotype was only significantly associated
with diabetic albuminuria among European Americans
from stage 1 and in the combined analysis. The findings
of stage 1 were not replicated in stage 2. The samples
from stage 1 and 2 were not randomly sampled, with
stage 1 consisting of a convenience sample enriched for
those with type 2 diabetes and African Americans, a
sample previously used for the study of genetic risk fac-
tors in cardiovascular disease and type 2 diabetes. Parti-
cipants comprising stage 2 consisted of the remaining
ARIC visit 4 particpants not in sample 1. However,
Enh2 TT still had an increased (but not statistically sig-
nificant) association with albuminuria among European
Americans with diabetes from stage 2, and had a signifi-
cant and strong association with diabetic albuminuria
when we combined both stages. Additionally, despite
the fact that our study included 8122 European Ameri-
cans, of whom there were 1095 type 2 diabetics, given
the rarity of the Enh2 TT risk genotype among diabetics
(6.6%), the size of our study precludes any definitive
conclusions regarding the association of type 2 diabetic
albuminuria and the Enh2 polymorphism of GLUT1.
Given this limitation, our study can at best suggest an
association between Enh2 and albuminuria among
European American type 2 diabetics; however, due to
the limitation in our number of subjects, we do not
have sufficient power to make conclusive statements
regarding this association. Perhaps a larger study of
type 2 diabetic European Americans involving multiple
cohorts may provide more power to definitively evaluate
the role of the Enh2 risk genotype of GLUT1 and albu-
minuria. Furthermore, we did not have hemoglobin A1C
(HbA1C) for all participants in our sample, though in
our sub-sample, adjustment did not significantly affect
results. Instead, we used fasting glucose as a marker of
glycemic control. However, Ng et al. had previously
found the strength of the association of the Enh2 risk
genotype and diabetic albuminuria was independent of
both HbA1C and duration of diabetes [5]. Ours is the
largest study of GLUT1 genetic variation and albumi-
nuria to date and the first to examine associations
among non-diabetics and African Americans. We sub-
stantiate prievous findings and extend the association
beyond type 1 diabetes, demonstrating a role for GLUT1
Enh2 and proteinuria among those with type 2 diabetes.
Conclusions
In summary, GLUT1 genetic variation of Enh2 may
predict risk of micro- and macroalbuminuria among
European Americans with type 2 diabetes. Though the
Enh2 risk genotype was significantly associated with dia-
betic albuminuria among European Americans from
stage 1 and in the combined analysis, the findings of
stage 1 were not replicated in stage 2. Furthermore, the
rarity of the Enh2 risk genotype among African Ameri-
cans precludes any definitive conclusions, although data
suggest a risk-enhancing role. Our results suggest the
Enh2 SNP, and not XbaI, is the causative polymorphism
associated with diabetic albuminuria. Additionally, the
Enh2 risk genotype may interact with hyperinsulinemia
to further increase susceptibility to albuminuria, consis-
tent with hypotheses generated by laboratory data.
Studying mechanisms mediating this association may
shed light on novel pathways and therapeutic targets in
the pathophysiology of albuminuria and nephropathy.
The modest size of the risk associated with GLUT1
Enh2 variation limits utility for screening, risk stratifica-
tion and individualized therapy. However, if multiple
genes of small and moderate effect on nephropathy are
identified, they may compose panels for risk assessment.
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